Immunology startup Dualitas Therapeutics secured $65 million to accelerate development of bispecific antibodies that simultaneously target two receptors on the same immune cell, offering superior modulation over monoclonal antibodies. Notable investors include Eli Lilly and Chugai Pharmaceutical, positioning Dualitas at the forefront of next-generation immunotherapy for inflammatory and autoimmune disorders. This funding round boosts bispecific biologics innovation.